NF-kappaB Serves As a Cellular Sensor of Kaposi's Sarcoma-associated Herpesvirus Latency and Negatively Regulates K-Rta by Antagonizing the RBP-Jkappa Coactivator
Overview
Affiliations
Successful viral replication is dependent on a conducive cellular environment; thus, viruses must be sensitive to the state of their host cells. We examined the idea that an interplay between viral and cellular regulatory factors determines the switch from Kaposi's sarcoma-associated herpesvirus (KSHV) latency to lytic replication. The immediate-early gene product K-Rta is the first viral protein expressed and an essential factor in reactivation; accordingly, this viral protein is in a key position to serve as a viral sensor of cellular physiology. Our approach aimed to define a host transcription factor, i.e., host sensor, which modulates K-Rta activity on viral promoters. To this end, we developed a panel of reporter plasmids containing all 83 putative viral promoters for a comprehensive survey of the response to both K-Rta and cellular transcription factors. Interestingly, members of the NF-kappaB family were shown to be strong negative regulators of K-Rta transactivation for all but two viral promoters (Ori-RNA and K12). Recruitment of K-Rta to the ORF57 and K-bZIP promoters, but not the K12 promoter, was significantly impaired when NF-kappaB expression was induced. Many K-Rta-responsive promoters modulated by NF-kappaB contain the sequence of the RBP-Jkappa binding site, a major coactivator which anchors K-Rta to target promoters via consensus motifs which overlap with that of NF-kappaB. Gel shift assays demonstrated that NF-kappaB inhibits the binding of RBP-Jkappa and forms a complex with RBP-Jkappa. Our results support a model in which a balance between K-Rta/RBP-Jkappa and NF-kappaB activities determines KSHV reactivation. An important feature of this model is that the interplay between RBP-Jkappa and NF-kappaB on viral promoters controls viral gene expression mediated by K-Rta.
Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases.
Inagaki T, Espera J, Wang K, Komaki S, Nair S, Davis R bioRxiv. 2025; .
PMID: 40027700 PMC: 11870588. DOI: 10.1101/2025.02.19.639178.
Rewriting Viral Fate: Epigenetic and Transcriptional Dynamics in KSHV Infection.
Han C, Niu D, Lan K Viruses. 2025; 16(12.
PMID: 39772181 PMC: 11680275. DOI: 10.3390/v16121870.
The cellular Notch1 protein promotes KSHV reactivation in an Rta-dependent manner.
DeCotiis-Mauro J, Han S, Mello H, Goyeneche C, Marchesini-Tovar G, Jin L J Virol. 2024; 98(8):e0078824.
PMID: 38975769 PMC: 11334469. DOI: 10.1128/jvi.00788-24.
KSHV vIL-6 enhances inflammatory responses by epigenetic reprogramming.
Inagaki T, Wang K, Kumar A, Izumiya C, Miura H, Komaki S PLoS Pathog. 2023; 19(11):e1011771.
PMID: 37934757 PMC: 10656005. DOI: 10.1371/journal.ppat.1011771.
Shimoda M, Inagaki T, Davis R, Merleev A, Tepper C, Maverakis E PLoS Pathog. 2023; 19(10):e1011703.
PMID: 37883374 PMC: 10602306. DOI: 10.1371/journal.ppat.1011703.